Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Reimbursement, Biologics Exclusivity Should Be Part Of EU Trade Talks, PhRMA And BIO Say

Executive Summary

Branded drug industry representatives presented a number of recommendations for U.S. negotiating priorities in upcoming trade talks with the European Union at a May 30 public hearing.

You may also be interested in...



Efforts To Adopt Path-Breaking Pharmaceutical Global Trade Rules In TPP Remains Work-In-Progress

Efforts to get a major new trade bloc to adopt stronger pharmaceutical intellectual property rules, including a potential path breaking agreement on biologics data exclusivity remains a work-in-progress, trade negotiators said at the end of the 18th round of the Trans-Pacific Partnership talks. But hope still floats the diverse group of 12 countries might find compromise language.

Trans-Pacific Partnership Pact Set As Test Ground For Getting Biologics Data Exclusivity At National Levels

While much of the talk on data exclusivity for biologics in the Trans-Pacific Partnership has been on the 12-year window in U.S. law, sources said current thinking is to get the other nations to agree to approve their own standards within a set time frame and use it as a template for future free trade agreements.

NICE Rejects Avastin For Ovarian Cancer On Cost, Okays Lucentis

NICE has knocked back Avastin for ovarian cancer due to high cost, but Roche may have a plausible market strategy in place for the drug in the UK.

Topics

UsernamePublicRestriction

Register

PS055381

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel